Daewon Pharmaceutical Co. Ltd. (003220) — Working Capital to Net Assets Ratio
Daewon Pharmaceutical Co. Ltd. (003220) has a Working Capital to Net Assets ratio of 13.7% as of March 2026. Working capital of ₩37.03 Billion (current assets of ₩238.49 Billion minus current liabilities of ₩201.46 Billion) is measured against net assets of ₩270.98 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Daewon Pharmaceutical Co. Ltd. defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Daewon Pharmaceutical Co. Ltd. Working Capital to Net Assets (2013–2025)
This chart shows how Daewon Pharmaceutical Co. Ltd.'s Working Capital to Net Assets ratio has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the ratio stands at 13.7%, reflecting working capital of ₩37.03 Billion against net assets of ₩270.98 Billion KRW. Check Daewon Pharmaceutical Co. Ltd. tangible equity quality to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Daewon Pharmaceutical Co. Ltd. (2013–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Daewon Pharmaceutical Co. Ltd. from 2013 to 2025, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see 003220 total asset value.
| Year | WC/NA Ratio | Working Capital (KRW) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 14.7% | ₩40.27 Billion | ₩274.58 Billion | ₩256.60 Billion | ₩216.34 Billion | ▼ -5.3 pp |
| 2024 | 20.0% | ₩56.79 Billion | ₩284.58 Billion | ₩257.57 Billion | ₩200.78 Billion | ▲ +9.9 pp |
| 2023 | 10.1% | ₩26.60 Billion | ₩264.26 Billion | ₩209.29 Billion | ₩182.69 Billion | ▼ -21.7 pp |
| 2022 | 31.8% | ₩79.14 Billion | ₩248.77 Billion | ₩207.28 Billion | ₩128.15 Billion | ▼ -4.0 pp |
| 2021 | 35.9% | ₩78.30 Billion | ₩218.40 Billion | ₩180.38 Billion | ₩102.08 Billion | ▲ +7.1 pp |
| 2020 | 28.8% | ₩61.26 Billion | ₩212.77 Billion | ₩117.28 Billion | ₩56.02 Billion | ▼ -0.5 pp |
| 2019 | 29.3% | ₩59.81 Billion | ₩204.22 Billion | ₩121.55 Billion | ₩61.74 Billion | ▲ +2.5 pp |
| 2018 | 26.8% | ₩49.03 Billion | ₩183.20 Billion | ₩106.72 Billion | ₩57.69 Billion | ▼ -6.9 pp |
| 2017 | 33.7% | ₩56.63 Billion | ₩168.13 Billion | ₩95.79 Billion | ₩39.16 Billion | ▼ -3.5 pp |
| 2016 | 37.2% | ₩60.23 Billion | ₩162.01 Billion | ₩95.07 Billion | ₩34.83 Billion | ▼ -2.3 pp |
| 2015 | 39.5% | ₩58.65 Billion | ₩148.66 Billion | ₩88.92 Billion | ₩30.27 Billion | ▼ -5.7 pp |
| 2014 | 45.1% | ₩60.73 Billion | ₩134.51 Billion | ₩92.24 Billion | ₩31.51 Billion | ▼ -2.4 pp |
| 2013 | 47.5% | ₩58.55 Billion | ₩123.25 Billion | ₩83.64 Billion | ₩25.09 Billion | — |